{"nctId":"NCT02549339","briefTitle":"Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up","startDateStruct":{"date":"2015-11-13","type":"ACTUAL"},"conditions":["Actinic Keratosis"],"count":383,"armGroups":[{"label":"LEO 43204 gel","type":"EXPERIMENTAL","interventionNames":["Drug: LEO 43204 gel"]},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle gel"]}],"interventions":[{"name":"LEO 43204 gel","otherNames":[]},{"name":"Vehicle gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on either the full face or a contiguous area of approximately 250 cm2 (40 in2) on the chest\n* Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 in2). The tracking area must be within the treatment area\n\nExclusion Criteria:\n\n* Location of the treatment area (full face or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC\n* Treatment with ingenol mebutate gel in the treatment area within the last 12 months\n* Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions)\n* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g., eczema, unstable psoriasis, xeroderma pigmentosum)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Clearance of Actinic Keratosis (AK)","description":"The number of clinically visible actinic keratosis lesions (AKs) identified in the treatment area was recorded at Day 1, Week 4, and Week 8.\n\nComplete clearance was defined as no clinically visible AKs in the treatment area.\n\nThe table shows the percentage of mean number of subjects across imputations with complete clearance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Clearance (Multiple Imputation)","description":"The number of clinically visible AKs identified in the treatment area was recorded at Day 1, Week 4, and Week 8.\n\nPartial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.\n\nThe table shows the percentage of mean number of participants across imputations with partial clearance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Clearance (Multiple Imputation)","description":"The number of clinically visible AKs identified in the treatment area was recorded at Day 1, Week 4, and Week 8.\n\nPartial clearance was defined as at least 75% reduction from baseline in the number of clinically visible AKs in the treatment area.\n\nThe table shows the percentage of mean number of participants across imputations with partial clearance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.1","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction in AK Count in the Treatment Area Compared to Baseline","description":"The percent reduction at Week 8 from baseline was analysed using a negative binomial regression for the AK count at Week 8 with treatment group and pooled sites as factors and baseline count as offset variable (using multiple imputations to account for missing values). The table presents adjusted mean percent reduction at Week 8 from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"15.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":202},"commonTop":["Application site pain","Application site pruritus","Basal cell carcinoma","Bowen's disease","Squamous cell carcinoma of skin"]}}}